{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T19:45:45Z","timestamp":1795117545315,"version":"4.10.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,17]]},"DOI":"10.7759\/cureus.86186","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T04:14:51Z","timestamp":1750133691000},"source":"Crossref","is-referenced-by-count":4,"title":["A Case of Umbilical Invasive Extramammary Paget Disease With a High Tumor Mutational Burden Successfully Treated With Pembrolizumab"],"prefix":"10.7759","author":[{"given":"Akihiro","family":"Ishiguro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Mae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryokichi","family":"Irisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000538675","article-title":"Recurrence of quadruple extramammary Paget's disease after 12 years: a case report and literature review","volume":"16","author":"Ishiguro A","year":"2024","unstructured":"Ishiguro A, Iwashita N, Abe M, Ogawa A, Takeo T, Watanabe D. Recurrence of quadruple extramammary Paget's disease after 12 years: a case report and literature review. Case Rep Dermatol. 2024, 16:149-55. 10.1159\/000538675","journal-title":"Case Rep Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.03.004","article-title":"Extramammary Paget disease of the axilla and scrotum in a Caucasian man","volume":"23","author":"Dai C","year":"2022","unstructured":"Dai C, Baird BA, Lyon TD, Sokumbi O, Degesys CA. Extramammary Paget disease of the axilla and scrotum in a Caucasian man. JAAD Case Rep. 2022, 23:87-9. 10.1016\/j.jdcr.2022.03.004","journal-title":"JAAD Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13200","article-title":"Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease","volume":"43","author":"Yoshino K","year":"2016","unstructured":"Yoshino K, Fujisawa Y, Kiyohara Y, et al.. Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease. J Dermatol. 2016, 43:633-7. 10.1111\/1346-8138.13200","journal-title":"J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7148","article-title":"Evidence-based clinical practice guidelines for extramammary Paget disease","volume":"8","author":"Kibbi N","year":"2022","unstructured":"Kibbi N, Owen JL, Worley B, et al.. Evidence-based clinical practice guidelines for extramammary Paget disease. JAMA Oncol. 2022, 8:618-28. 10.1001\/jamaoncol.2021.7148","journal-title":"JAMA Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2011.23.4.519","article-title":"Apocrine carcinoma of the groin possibly associated with extramammary Paget's disease","volume":"23","author":"Seo SH","year":"2011","unstructured":"Seo SH, Shin DH, Sung HW. Apocrine carcinoma of the groin possibly associated with extramammary Paget's disease. Ann Dermatol. 2011, 23:519-22. 10.5021\/ad.2011.23.4.519","journal-title":"Ann Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al.. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020, 21:1353-65. 10.1016\/S1470-2045(20)30445-9","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17500","article-title":"Extramammary Paget's disease treated with of anti-programmed cell death protein 1 therapy after docetaxel therapy failure","volume":"52","author":"Narasaki M","year":"2025","unstructured":"Narasaki M, Kato J, Sato S, et al.. Extramammary Paget's disease treated with of anti-programmed cell death protein 1 therapy after docetaxel therapy failure. J Dermatol. 2025, 52:359-62. 10.1111\/1346-8138.17500","journal-title":"J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02524-0","article-title":"PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs: approval of nivolumab for unresectable advanced or recurrent epithelial skin malignancies in Japan","volume":"29","author":"Matsumura N","year":"2024","unstructured":"Matsumura N, Mandai M. PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs: approval of nivolumab for unresectable advanced or recurrent epithelial skin malignancies in Japan. Int J Clin Oncol. 2024, 29:639. 10.1007\/s10147-024-02524-0","journal-title":"Int J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.72592","article-title":"A case of advanced extramammary Paget's disease with a high tumor mutation burden that showed partial lymph node regression with pembrolizumab","volume":"16","author":"Horisaki K","year":"2024","unstructured":"Horisaki K, Taki T, Mori S, Okumura M, Akiyama M. A case of advanced extramammary Paget's disease with a high tumor mutation burden that showed partial lymph node regression with pembrolizumab. Cureus. 2024, 16:e72592. 10.7759\/cureus.72592","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.03.018","article-title":"Pseudoprogression and hyperprogression after checkpoint blockade","volume":"58","author":"Wang Q","year":"2018","unstructured":"Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol. 2018, 58:125-35. 10.1016\/j.intimp.2018.03.018","journal-title":"Int Immunopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das S","year":"2019","unstructured":"Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019, 7:306. 10.1186\/s40425-019-0805-8","journal-title":"J Immunother Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2563","article-title":"Early incidence of immune-related adverse events (irAEs) predicts efficacy in patients (pts) with solid tumors treated with immune-checkpoint inhibitors (ICIs)","volume":"37","author":"Morehouse C","year":"2019","unstructured":"Morehouse C, Abdullah SE, Dar M, Ranade K, Higgs B. Early incidence of immune-related adverse events (irAEs) predicts efficacy in patients (pts) with solid tumors treated with immune-checkpoint inhibitors (ICIs). J Clin Oncol. 2019, 37:2653. 10.1200\/JCO.2019.37.15_suppl.2563","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar S","year":"2019","unstructured":"Manohar S, Kompotiatis P, Thongprayoon C, Cheungpasitporn W, Herrmann J, Herrmann SM. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant. 2019, 34:108-17. 10.1093\/ndt\/gfy105","journal-title":"Nephrol Dial Transplant"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02340219","article-title":"AKI in patients receiving immune checkpoint inhibitors","volume":"14","author":"Perazella MA","year":"2019","unstructured":"Perazella MA, Sprangers B. AKI in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019, 14:1077-9. 10.2215\/CJN.02340219","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/356229-a-case-of-umbilical-invasive-extramammary-paget-disease-with-a-high-tumor-mutational-burden-successfully-treated-with-pembrolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T04:14:51Z","timestamp":1750133691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/356229-a-case-of-umbilical-invasive-extramammary-paget-disease-with-a-high-tumor-mutational-burden-successfully-treated-with-pembrolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.86186","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}